New accurate dosing solution to help medical marijuana patients

799 0

“Accudose” should help medical marijuana users control their use

One of the issues with medical marijuana is ensuring that a proper dose is administered each and every time. This limitation is the result of a lack of widespread dosing solutions, but Grenco Science believes it has the answer. It has teamed up with Vapium, a vaporization company that is part of Jonson & Johnson Innovations, to introduce Accudose, an “accurate dosing technology for cannabis consumption.”

Grenco and Vapium will use the latter’s dose control technology and its hardware in conjunction with Grenco’s brand partners, including Caliva, FlowerOne and Harvest Health, to introduce dose-metered cannabis consumption solutions. Grenco’s founder and CEO, Chris Folkerts, explains, “Grenco Science is excited to partner with Vapium and bring Accudose into our growing portfolio of brand partners. After seeing the technology Vapium created, this was a clear fit for the multi-state model we developed to launch [our products].”

“This partnership will allow us to introduce a product offering into the medical cannabis industry with the first actual accurate dosing technology which has not yet been seen on the market and will propel Accudose to become a leader in the industry,” he adds.

Vapium has received a lot of attention for its innovative solutions. It has found investments from heavy-hitters such as Canopy Growth and the company’s co-founder and CEO, Michael Trzecieski, states, “From the inception of Vapium, our primary focus has always been patient-centric. We’ve worked hard to fully consider the medical conditions faced by users and created a revolutionary platform. It will empower patients and practitioners. We are thrilled to be launching this with Grenco so that the world will benefit.

“Grenco’s multi state filling ecosystem coupled with their international brand recognition is nothing short of remarkable. Combining this infrastructure with our years of medical research, dosing and analytic capabilities, we are uniquely positioned to drive the transparency and efficacy needed to standardize cannabis as medicine.”